A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Argenx Se stock. As of the latest transaction made, Citadel Advisors LLC holds 28,700 shares of ARGX stock, worth $16.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,700
Previous 33,400 14.07%
Holding current value
$16.9 Million
Previous $13.2 Million 6.14%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $193 Million - $244 Million
540,814 Added 481.68%
653,090 $281 Million
Q1 2024

May 15, 2024

SELL
$356.95 - $413.29 $27.2 Million - $31.4 Million
-76,083 Reduced 40.39%
112,276 $44.2 Million
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $84 Million - $125 Million
-247,764 Reduced 56.81%
188,359 $71.7 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $27.9 Million - $41.4 Million
75,535 Added 20.95%
436,123 $214 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $120 Million - $141 Million
333,055 Added 1209.66%
360,588 $141 Million
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $31.9 Million - $38.6 Million
-95,564 Reduced 77.63%
27,533 $10.3 Million
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $31.4 Million - $36.9 Million
91,819 Added 293.56%
123,097 $46.6 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $18.7 Million - $21.6 Million
-54,455 Reduced 63.52%
31,278 $11 Million
Q2 2022

Aug 15, 2022

BUY
$269.58 - $378.88 $15.5 Million - $21.7 Million
57,367 Added 202.24%
85,733 $32.5 Million
Q4 2021

Feb 14, 2022

BUY
$272.01 - $353.03 $1.6 Million - $2.07 Million
5,865 Added 26.07%
28,366 $9.93 Million
Q3 2021

Nov 15, 2021

BUY
$295.0 - $350.58 $4.46 Million - $5.3 Million
15,128 Added 205.18%
22,501 $6.8 Million
Q2 2021

Aug 16, 2021

SELL
$257.11 - $319.92 $12.1 Million - $15.1 Million
-47,048 Reduced 86.45%
7,373 $2.22 Million
Q1 2021

May 17, 2021

BUY
$268.3 - $380.31 $4.72 Million - $6.7 Million
17,608 Added 47.83%
54,421 $15 Million
Q4 2020

Feb 16, 2021

BUY
$248.13 - $308.36 $8.1 Million - $10.1 Million
32,648 Added 783.87%
36,813 $10.8 Million
Q3 2020

Nov 16, 2020

SELL
$215.51 - $272.51 $4.75 Million - $6 Million
-22,018 Reduced 84.09%
4,165 $1.09 Million
Q2 2020

Aug 14, 2020

BUY
$127.44 - $232.72 $2.18 Million - $3.98 Million
17,113 Added 188.68%
26,183 $5.9 Million
Q1 2020

May 15, 2020

SELL
$108.83 - $165.23 $836,032 - $1.27 Million
-7,682 Reduced 45.86%
9,070 $1.2 Million
Q4 2019

Feb 14, 2020

SELL
$106.59 - $164.21 $1.02 Million - $1.58 Million
-9,597 Reduced 36.42%
16,752 $2.69 Million
Q3 2019

Nov 14, 2019

BUY
$113.31 - $150.51 $1.28 Million - $1.7 Million
11,294 Added 75.02%
26,349 $3 Million
Q2 2019

Aug 14, 2019

BUY
$115.0 - $141.58 $771,880 - $950,284
6,712 Added 80.45%
15,055 $2.13 Million
Q1 2019

May 15, 2019

SELL
$98.85 - $134.59 $1.52 Million - $2.07 Million
-15,413 Reduced 64.88%
8,343 $0
Q4 2018

Feb 14, 2019

SELL
$63.81 - $109.82 $6.54 Million - $11.2 Million
-102,427 Reduced 81.17%
23,756 $2.28 Million
Q3 2018

Nov 13, 2018

BUY
$75.5 - $96.63 $4.97 Million - $6.36 Million
65,768 Added 108.86%
126,183 $0
Q2 2018

Aug 10, 2018

SELL
$74.84 - $100.16 $3.55 Million - $4.75 Million
-47,381 Reduced 43.95%
60,415 $0
Q1 2018

May 11, 2018

BUY
$56.95 - $85.19 $6.14 Million - $9.18 Million
107,796 New
107,796 $8.67 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $32.6B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.